Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A-ECO red blood cells
- Development stage
- Phase 1
- Lead developer
- Velico
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
A-ECO red blood cells are a cell therapy product consisting of group A red blood cells that have been enzymatically modified to remove the A-antigen from their surface, effectively converting them into group O (universal donor) cells. Developed by Velico Medical, this technology utilizes specific recombinant alpha-N-acetylgalactosaminidases (glycosidases) to cleave the terminal alpha-1,3-linked N-acetylgalactosamine residue that defines the A blood group. By converting the A-antigen into the H-antigen found on group O cells, the product aims to mitigate the risk of hemolytic transfusion reactions and address shortages in the supply of O-negative and O-positive universal donor blood. Clinical development has focused on evaluating the safety, immunogenicity, and post-transfusion survival of these converted cells in autologous and allogeneic settings.
- Other names
- Enzyme-converted A-to-O red blood cellsEnzyme-converted A-to-O red cellsECO-RBCEnzyme converted group O red blood cells
02
Targets
A antigen (Blood group A antigen)B antigen (ABO blood group B antigen)
Beyond the preview
Go deeper on A-ECO red blood cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A-ECO red blood cells.